Wockhardt Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Wockhardt has a total shareholder equity of ₹36.6B and total debt of ₹23.6B, which brings its debt-to-equity ratio to 64.3%. Its total assets and total liabilities are ₹76.5B and ₹39.9B respectively. Wockhardt's EBIT is ₹540.0M making its interest coverage ratio 0.2. It has cash and short-term investments of ₹5.2B.
Anahtar bilgiler
64.3%
Borç/özkaynak oranı
₹23.56b
Borç
| Faiz karşılama oranı | 0.2x |
| Nakit | ₹5.23b |
| Eşitlik | ₹36.62b |
| Toplam yükümlülükler | ₹39.87b |
| Toplam varlıklar | ₹76.49b |
Son finansal sağlık güncellemeleri
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Recent updates
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
Nov 02What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You
Aug 20Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Jun 30Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation
Jun 22Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: WOCKPHARMA's short term assets (₹21.8B) do not cover its short term liabilities (₹27.9B).
Uzun Vadeli Yükümlülükler: WOCKPHARMA's short term assets (₹21.8B) exceed its long term liabilities (₹12.0B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: WOCKPHARMA's net debt to equity ratio (50.1%) is considered high.
Borcun Azaltılması: WOCKPHARMA's debt to equity ratio has reduced from 112.3% to 64.3% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: Whilst unprofitable WOCKPHARMA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Tahmini Nakit Akışı: WOCKPHARMA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 18.3% per year.